Production (Stage)
Telomir Pharmaceuticals, Inc.
TELO
$2.07
-$0.03-1.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 33.89% | -26.48% | -442.61% | -580.57% | -1,383.39% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -100.00% | 169.20% | 485.65% | 4,598.47% | -- |
| Total Other Non-Cash Items | 11.84% | -6.54% | 90,851.85% | 7,486,600.00% | -- |
| Change in Net Operating Assets | -73.55% | 10.97% | -84.82% | -173.78% | 161.86% |
| Cash from Operations | 21.12% | -31.36% | -83.32% | -491.67% | -344.52% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -100.00% | -100.00% | -53.48% | 240.29% | 693.18% |
| Total Debt Repaid | -329.60% | -- | -211.46% | -- | -- |
| Issuance of Common Stock | -82.49% | 530.30% | 461.42% | 461.42% | 461.42% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 201.54% | 100.00% | -94.75% | 75.84% | -64.40% |
| Cash from Financing | -86.53% | 64.14% | 111.08% | 656.42% | 633.42% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -187.74% | 632,550.00% | 21,438.46% | 31,583.05% | 131,000.00% |